Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis. [Beobachtende Folgestudie um die Langzeit-Verträglichkeit und Wirksamkeit (Häufigkeit des Wiederauftretens von AK-Läsionen) von Resiquimod Gel bei Patienten mit aktinischer Keratose, die zuvor mit Resiquimod Gel behandelt wurden, zu untersuchen. [Erweiterungsversuch zum klinischen Versuch SP848AK1101]] [EXTENSION OF 700216015]

X
Trial Profile

Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis. [Beobachtende Folgestudie um die Langzeit-Verträglichkeit und Wirksamkeit (Häufigkeit des Wiederauftretens von AK-Läsionen) von Resiquimod Gel bei Patienten mit aktinischer Keratose, die zuvor mit Resiquimod Gel behandelt wurden, zu untersuchen. [Erweiterungsversuch zum klinischen Versuch SP848AK1101]] [EXTENSION OF 700216015]

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resiquimod (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 29 May 2013 Planned end date changed from 1 Apr 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 06 Mar 2013 Planned End Date (Apr 2015) added as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top